Plus Therapeutics announced that the Company will present data from its ReSPECT-LM clinical trial evaluating the Company’s lead radiotherapeutic, rhenium obisbemeda, for the treatment of leptomeningeal metastases at the Cancer Prevention & Research Institute of Texas Innovations in Cancer Prevention and Research Conference VI. The conference is taking place October 2-3, 2023, in Galveston, Tex. In August 2023, Plus Therapeutics received an advance payment of grant funds of approximately $1.9M, as planned, as part of its overall $17.6M award contract, which CPRIT executed in September 2022. The contract provides for funding from CPRIT over the three-year grant period starting on August 31, 2022, and follows the expected increase of development costs as the ReSPECT-LM clinical trial progresses to later stages.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PSTV:
- Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
- Biocept, Plus Therapeutics enter licensing agreement for CNSide
- Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay
- Plus Therapeutics expands supply agreement with Biocept
- Plus Therapeutics begins Part B of Phase 1/2a trial for leptomenin metastase